Illumina, Inc.
ILMNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Illumina, Inc. (ILMN) is listed under Diagnostics & Research. The company carries a $32.95B market cap, placing it firmly in the large-cap category. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Market Cap
$32.95B
Beta
1.47
P/E (TTM)
40.64
P/E (Fwd)
35.78
EPS (TTM)
$5.37
EPS (Fwd)
$6.10
ROE
32.3%
ROA
8.7%
Cash
$1.17B
Total Debt
$2.53B
Free CF
$797.6M
52W Change
122.2%
Annual Financials
Cash vs Debt
Where ILMN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ILMN finished 36.81% above its 150-day moving average ($155.87) and 41.34% above its 200-day moving average ($150.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ILMN overbought or oversold?
At the September 3, 2026 close, ILMN's RSI(14) was 63.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ILMN has $1.17B in cash with $2.53B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $797.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 32.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $4.58B (2022) to $4.34B (2025).
Investors considering Illumina, Inc. should weigh the typical risks associated with ILMN's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ILMN.